Gilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies

57
2
Favorite

Gilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies

MarketWatch2022-09-12

Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise.

The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said it agreed to a non-exclusive license with several generic drug manufacturers - Cipla Ltd., Lupin Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., and Hetero Labs Ltd. - that first goes into effect in 2031.

"This settlement will [meaningfully] extend the exclusivity of several key HIV agents including Descovy, Vemlidy, and Odefsey to 2031 and 2032 (for Odefsey)," RBC Capital Markets analyst Brian Abrahams wrote Monday.

Gilead's stock is down 10.1% this year, while the broader S&P 500 has declined 14.6%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（2）

skyel
·2022-09-13
Ok
Reply
1
Report
逢場作戲又一日
·2022-09-12
Great
Reply
Like
Report

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1130022155?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-12 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130022155","market":"us","top_or_hot":-1,"title":"Gilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies","media":"MarketWatch","content":"<html><head></head><body><p>Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. </p><p><img src=\"https://static.tigerbbs.com/227368f126467272602647c575b929f3\" tg-width=\"829\" tg-height=\"815\" width=\"100%\" height=\"auto\"/></p><p>The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said it agreed to a non-exclusive license with several generic drug manufacturers - Cipla Ltd., Lupin Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., and Hetero Labs Ltd. - that first goes into effect in 2031. </p><p>&#34;This settlement will [meaningfully] extend the exclusivity of several key HIV agents including Descovy, Vemlidy, and Odefsey to 2031 and 2032 (for Odefsey),&#34; RBC Capital Markets analyst Brian Abrahams wrote Monday. </p><p>Gilead&#39;s stock is down 10.1% this year, while the broader S&amp;P 500 has declined 14.6%.</p></body></html>","source":"lsy1603348471595","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-12 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise...</p>\n\n<a href=\"https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews","article_id":"1130022155","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130022155","pubTimestamp":1662988392,"columns":[],"sourceInfo":{"source_id":"lsy1603348471595","name":"MarketWatch"},"weMediaInfo":null,"summary":"Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"Gilead的股票在与HIV疗法有关的专利案件后上涨了5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said it agreed to a non-exclusive license with several generic drug manufacturers - Cipla Ltd., Lupin Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., and Hetero Labs Ltd. - that first goes into effect in 2031. \"This settlement will [meaningfully] extend the exclusivity of several key HIV agents including Descovy, Vemlidy, and Odefsey to 2031 and 2032 (for Odefsey),\" RBC Capital Markets analyst Brian Abrahams wrote Monday. Gilead's stock is down 10.1% this year, while the broader S&P 500 has declined 14.6%.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":9935327667,"gmtCreate":1663035307160,"gmtModify":1676537188217,"author":{"id":"3581505866102985","authorId":"3581505866102985","name":"skyel","avatar":"https://static.tigerbbs.com/a4e416c9b1fabad56fbe0e086388d5b0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3581505866102985","authorIdStr":"3581505866102985"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9935327667","repostId":1130022155,"repostType":4,"repost":{"id":"1130022155","kind":"news","pubTimestamp":1662988392,"share":"https://ttm.financial/m/news/1130022155?lang=&edition=fundamental","pubTime":"2022-09-12 21:13","market":"us","language":"en","title":"Gilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1130022155","media":"MarketWatch","summary":"Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in","content":"<html><head></head><body><p>Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. </p><p><img src=\"https://static.tigerbbs.com/227368f126467272602647c575b929f3\" tg-width=\"829\" tg-height=\"815\" width=\"100%\" height=\"auto\"/></p><p>The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said it agreed to a non-exclusive license with several generic drug manufacturers - Cipla Ltd., Lupin Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., and Hetero Labs Ltd. - that first goes into effect in 2031. </p><p>&#34;This settlement will [meaningfully] extend the exclusivity of several key HIV agents including Descovy, Vemlidy, and Odefsey to 2031 and 2032 (for Odefsey),&#34; RBC Capital Markets analyst Brian Abrahams wrote Monday. </p><p>Gilead&#39;s stock is down 10.1% this year, while the broader S&amp;P 500 has declined 14.6%.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-12 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise...</p>\n\n<a href=\"https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130022155","content_text":"Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said it agreed to a non-exclusive license with several generic drug manufacturers - Cipla Ltd., Lupin Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., and Hetero Labs Ltd. - that first goes into effect in 2031. \"This settlement will [meaningfully] extend the exclusivity of several key HIV agents including Descovy, Vemlidy, and Odefsey to 2031 and 2032 (for Odefsey),\" RBC Capital Markets analyst Brian Abrahams wrote Monday. Gilead's stock is down 10.1% this year, while the broader S&P 500 has declined 14.6%.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9932798849,"gmtCreate":1662989439281,"gmtModify":1676537177025,"author":{"id":"3555043402922696","authorId":"3555043402922696","name":"逢場作戲又一日","avatar":"https://community-static.tradeup.com/news/6a5fbf2ceb7c7ee0399d41e6348dadf7","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":12,"crmLevelSwitch":1,"idStr":"3555043402922696","authorIdStr":"3555043402922696"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9932798849","repostId":1130022155,"repostType":4,"repost":{"id":"1130022155","kind":"news","pubTimestamp":1662988392,"share":"https://ttm.financial/m/news/1130022155?lang=&edition=fundamental","pubTime":"2022-09-12 21:13","market":"us","language":"en","title":"Gilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1130022155","media":"MarketWatch","summary":"Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in","content":"<html><head></head><body><p>Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. </p><p><img src=\"https://static.tigerbbs.com/227368f126467272602647c575b929f3\" tg-width=\"829\" tg-height=\"815\" width=\"100%\" height=\"auto\"/></p><p>The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said it agreed to a non-exclusive license with several generic drug manufacturers - Cipla Ltd., Lupin Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., and Hetero Labs Ltd. - that first goes into effect in 2031. </p><p>&#34;This settlement will [meaningfully] extend the exclusivity of several key HIV agents including Descovy, Vemlidy, and Odefsey to 2031 and 2032 (for Odefsey),&#34; RBC Capital Markets analyst Brian Abrahams wrote Monday. </p><p>Gilead&#39;s stock is down 10.1% this year, while the broader S&amp;P 500 has declined 14.6%.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead's Stock Jumps 5% after Setting Patent Case Related to HIV Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-12 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise...</p>\n\n<a href=\"https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.marketwatch.com/story/gileads-stock-jumps-5-after-setting-patent-case-related-to-hiv-therapies-2022-09-12?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130022155","content_text":"Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada. Gilead said it agreed to a non-exclusive license with several generic drug manufacturers - Cipla Ltd., Lupin Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., and Hetero Labs Ltd. - that first goes into effect in 2031. \"This settlement will [meaningfully] extend the exclusivity of several key HIV agents including Descovy, Vemlidy, and Odefsey to 2031 and 2032 (for Odefsey),\" RBC Capital Markets analyst Brian Abrahams wrote Monday. Gilead's stock is down 10.1% this year, while the broader S&P 500 has declined 14.6%.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":57,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}